JPS6357521A - Oral preparation - Google Patents
Oral preparationInfo
- Publication number
- JPS6357521A JPS6357521A JP61202143A JP20214386A JPS6357521A JP S6357521 A JPS6357521 A JP S6357521A JP 61202143 A JP61202143 A JP 61202143A JP 20214386 A JP20214386 A JP 20214386A JP S6357521 A JPS6357521 A JP S6357521A
- Authority
- JP
- Japan
- Prior art keywords
- indomethacin
- metasilicate
- magnesium
- oral preparation
- blended
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims abstract description 59
- 229960000905 indomethacin Drugs 0.000 claims abstract description 29
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000008280 blood Substances 0.000 abstract description 8
- 210000004369 blood Anatomy 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 3
- 238000002156 mixing Methods 0.000 abstract description 3
- 208000025865 Ulcer Diseases 0.000 abstract description 2
- 230000000202 analgesic effect Effects 0.000 abstract description 2
- 239000002221 antipyretic Substances 0.000 abstract description 2
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 abstract description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract description 2
- 231100000397 ulcer Toxicity 0.000 abstract description 2
- 230000007721 medicinal effect Effects 0.000 abstract 2
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 abstract 1
- 230000001754 anti-pyretic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 20
- 238000009472 formulation Methods 0.000 description 13
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 12
- 238000012360 testing method Methods 0.000 description 9
- 239000008101 lactose Substances 0.000 description 8
- -1 magnesium aluminate Chemical class 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 6
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000007963 capsule composition Substances 0.000 description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 101100390778 Drosophila melanogaster Fitm2 gene Proteins 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003907 antipyretic analgesic agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は、インドメタシン経口製剤に関し、さらに詳し
くはメタケイ酸アルミン酸マグネシウＬを添加すること
を特徴とする経口製剤に関する。DETAILED DESCRIPTION OF THE INVENTION [Industrial Application Field] The present invention relates to an oral preparation of indomethacin, and more particularly to an oral preparation characterized by adding magnesium aluminate L metasilicate.
インドメタシン（１−（ｐ−クロロベンゾイル）−５−
メトキシ−２−メチルインドール−３＝酢酸、 ０１ｇ
Ｈ１６ＣｔＮＯ４（分子量、３５７．７９ ） ）は非
ステロイド系抗炎症剤で、鎮痛、解熱薬として広く用い
られている。Indomethacin (1-(p-chlorobenzoyl)-5-
Methoxy-2-methylindole-3=acetic acid, 01g
H16CtNO4 (molecular weight, 357.79) is a non-steroidal anti-inflammatory drug that is widely used as an analgesic and antipyretic drug.
何ら処置をしない場合、インドメタシン製剤からのイン
ドメタシンの最高血中濃度到達時間（′ＩｍＸ）は１〜
３時間であシ、〔バッカーら、ジャーナルオプ ファー
マコロジー アンド エクスペリメンタル セラビュー
ティックス（Ｊ、 Ｐｈａｒｍａｃｏｌ。If no treatment is taken, the time to reach the maximum blood concentration of indomethacin from indomethacin preparations ('ImX) is 1 to
3 hours, [Backer et al., Journal of Pharmacology and Experimental Therapeutics (J, Pharmacol.
Ｅｘｐ、−、？ｈｅｒ ）第１５３巻、第２３７頁、１
９６６年〕、〔ダガンら、同誌、第１８１巻、第５６３
頁、１９７２年〕、〔アダムスら、ブリティッシュジャ
ーナル オプ クリニカル ファーマコロジ−（Ｂｒ、
Ｊ、 ｃｌｉｎ、 Ｐｈａｒｍａｃ、 ）第１４巻、
第２８６頁、１９８２年〕速効性を必要とする解熱鎮痛
剤としては不十分である。Exp, -,? her) Volume 153, Page 237, 1
966], [Duggan et al., same journal, vol. 181, no. 563
Page, 1972], [Adams et al., British Journal of Clinical Pharmacology (Br,
J, Clin, Pharmac, ) Volume 14,
p. 286, 1982] It is insufficient as an antipyretic analgesic that requires rapid action.
本発明の目的は最高血中濃度到達時間（Ｔｍａｘ）が短
いインドメタシン経口製剤を提供することにある。An object of the present invention is to provide an oral preparation of indomethacin with a short time to maximum blood concentration (Tmax).
本発明者らは、上述の問題に鑑み、鋭意検討を重ねた結
果、インドメタシンに対し、２０重量％以上好ましくは
５０〜２００重量％のメタケイ酸アルミン酸マグネシウ
ムを添加剤として加えることにより、最高血中濃度到達
時間（Ｔｍａｘ ）を早め、バイオアベイラビリティ−
を高めることができだ。In view of the above-mentioned problems, the present inventors have conducted extensive studies and found that by adding 20% or more by weight or more preferably 50 to 200% by weight of magnesium aluminate metasilicate to indomethacin as an additive, it is possible to improve blood flow by increasing blood pressure. Accelerates the time to medium concentration (Tmax) and improves bioavailability.
It is possible to increase
すなわち、インドメタシンに対し、メタケイ酸アルミン
酸マグネシウムを１０重量％添加したものではＴｍａｘ
および血中濃度曲線下面積（ＡＵＣ）とも対照品と同等
であるのに対し、２０重量％添加するとＴｍａｘが速く
なシ、吸収が良くなる。さらに、１００重量％添加する
ことによＦ） 、Ｔｍａｘは対照品の約％時間となり、
ＡＵＣは約２倍の値を示した。ここでインドメタシンに
対し、２０重量％以上の割合でメタケイ酸アルミン酸マ
グネシウムを添加することによって、速効性で、かつ、
バイオアベイラビリティ−を高めることができた。That is, when 10% by weight of magnesium aluminate metasilicate is added to indomethacin, Tmax
Both the area under the blood concentration curve (AUC) and the area under the blood concentration curve (AUC) were the same as the control product, whereas adding 20% by weight resulted in a faster Tmax and better absorption. Furthermore, by adding 100% by weight of F), Tmax becomes approximately % time of the control product,
AUC showed approximately twice the value. Here, by adding magnesium aluminate metasilicate to indomethacin at a ratio of 20% by weight or more, it is fast-acting and
Bioavailability could be increased.
一方、配合割合の上限に関しては、特に制限するもので
はないが、インドメタシンの３倍量を越えて配合すると
、製剤上嵩高くなってしまい、実用上、１回の投与量が
増すなどの問題を生じる。On the other hand, there is no particular restriction on the upper limit of the blending ratio, but if more than three times the amount of indomethacin is blended, the formulation will be bulky, and in practical terms, problems such as an increase in the dose per dose may occur. arise.
好ましくは、インドメタシンに対し、２００重量％以下
であり、この範囲内の添加量であれば、インドメタシン
製剤の吸収性を改良するだけでなく、製剤設計上問題が
無い。Preferably, the amount is 200% by weight or less based on indomethacin, and if the amount is within this range, not only the absorbability of the indomethacin preparation is improved, but there is no problem in the formulation design.
本経口製剤を製造するに当シ、剤形を特に規定するもの
ではない。例えば、錠剤、丸斉に顆粒剤、細粒剤、散剤
、トローチ剤、カプセル剤などが挙げられる。There are no particular restrictions on the dosage form for producing this oral preparation. Examples include tablets, whole granules, fine granules, powders, troches, capsules, and the like.
本発明に係るメタケイ酸アルミン酸マグネシウム配合イ
ンドメタシン製剤は、従来のものに比べ、速く薬効を発
揮することができる。また従来のものと同等の薬効を発
揮させるだめのインドメタシン配合量を少なくすること
ができることから、潰瘍形成等の副作用を低減させるだ
けでなく、製剤の小型化およびコストの低減をもたらす
。The indomethacin formulation containing magnesium aluminate metasilicate according to the present invention can exhibit its medicinal efficacy more quickly than conventional formulations. Furthermore, since it is possible to reduce the amount of indomethacin that is required to exert the same medicinal efficacy as conventional drugs, it not only reduces side effects such as ulcer formation, but also results in smaller formulations and lower costs.
（実施例）
以下、実施例及び試験例をもって本発明を具体的に説明
する。(Examples) Hereinafter, the present invention will be specifically explained using Examples and Test Examples.
実施例 １
インドメタシン５０２、低置換度ヒドロキシプロピルセ
ルロース ７０２及び乳１ｉ １５３．５ｆから成る
均質な粉末混合物を調製し、常法によシ顆粒化した。別
にメタケイ酸アルミン酸マグネシウム１０２、軽質無水
ケイ酸４．５１を均質化した。２つの粉末混合物を合わ
せ、さらにタルク１２．Ｏｆを加えて、混合均質化した
のち、常法により５号カプセル２０００個に充填し、１
カプセル当シ以下に示す処方製剤を得た。Example 1 A homogeneous powder mixture consisting of indomethacin 502, low substituted hydroxypropylcellulose 702 and milk 1i 153.5f was prepared and granulated in a conventional manner. Separately, 102 parts of magnesium aluminate metasilicate and 4.5 parts of light anhydrous silicic acid were homogenized. Combine the two powder mixtures and add 12. After adding Of and homogenizing it, it was filled into 2,000 No. 5 capsules by the usual method, and 1
A capsule formulation was obtained as shown below.
インドメタシン ２５．００■メタケ
イ酸アルミン酸マグネシウム ５．００■低ｆ
ｆｉｔＭヒドロキシプロピルセルロース ３５．００
■乳 糖 ７
６．７５■軽質無水ケイ酸 ２．２
５Ｗｌｉタルク ６．００
■１５０．００■
実施例 ２
実施例１記載の方法に従って、下記組成のカプセル製剤
を製造した。Indomethacin 25.00■Magnesium aluminate metasilicate 5.00■Low f
fitM hydroxypropylcellulose 35.00
■Lactose 7
6.75 ■ Light silicic anhydride 2.2
5Wli Talc 6.00
■150.00■ Example 2 According to the method described in Example 1, a capsule formulation having the following composition was manufactured.
インドメタシン ２５． ＯＯ■メタ
ケイ酸アルミン酸マグネシウム ２５．００〜低
置換ｉヒドロキシプロピルセルロース ３ｓ、ｏｏ１
ｒＮ！乳 糖
７６．７５■軽質無水ケイ酸 ２
，２５ηタルク６、 ＯＯｍ９
１７０．００η
実施例 ３
メタケイ酸アルミン酸マグネシウム １５０７、軽質無
水ケイ酸 ６０２を混合し、均質化した。Indomethacin 25. OO ■ Magnesium metasilicate aluminate 25.00 ~ Low substituted i Hydroxypropyl cellulose 3s, oo1
rN! lactose
76.75 ■ Light silicic anhydride 2
, 25η Talc 6, OOm9 170.00η Example 3 Magnesium metasilicate aluminate 1507 and light silicic anhydride 602 were mixed and homogenized.
その後乳糖 ５４０ ？、インドメタシン ５０１、デ
ンプン ８５０？を加えて混合した。さらにヒドロキシ
プロピルセルロース
５０〇−加えて溶解したものを結合剤として、混練した
のち、常法に従って、１包当り、以下の処方に示す顆粒
剤２ ０ ０ ０ ｍを製造した。Then lactose 540? , indomethacin 501, starch 850? was added and mixed. Further, 500 ml of hydroxypropyl cellulose was added and dissolved as a binder, and after kneading, 2000 m of granules according to the following formulation were produced per package according to a conventional method.
インドメタシン ２５．ＯＣ１ｍｑメ
タケイ酸アルミン酸マグネシウム ７５．００〜
デンプン ４２５．００■乳
糖 ４２０． Ｏ
Ｏ■軽質無水ケ・ｆ酸 ３０．００■
ヒドロキンプロピルセルロース ２５．００
η１ｏｏｏ、ｏｏ■
実施例 ４
メタケイ酸アルミン酸マグネシウム ５０２、軽質無水
ケイ酸 １００ｆ、乳糖 １７５０Ｆ、インドメタシン
５０２を加えて混合した。Indomethacin 25. OC1mq Magnesium metasilicate aluminate 75.00~
Starch 425.00 ■Milk
Sugar 420. O
O ■Light anhydrous acid 30.00■
Hydroquine propyl cellulose 25.00
η1ooo, oo■ Example 4 Magnesium metasilicate aluminate 502, light anhydrous silicic acid 100F, lactose 1750F, and indomethacin 502 were added and mixed.
サラニヒドロキシプｏビルセルロース ５ｏ２に精製水
５０〇−加えて溶解したものを結合剤として混練し、
乾燥した。その°後、常法に従って粉砕し、１包当り、
以下の処方に示す散剤２００゜包を製造した。Add purified water 500 to Sarani Hydroxypovir Cellulose 502 and knead as a binder,
Dry. After that, it is crushed according to the usual method, and each package contains
A 200° packet of the powder shown in the following formulation was manufactured.
インドメタシン ２５．０ＯＷｌメタ
ケイ酸アルミ／酸マグネ／ウム ２５．００■乳
糖 ８７５．００■
軽質無水ケイ酸 ５０００■ヒドロキシ
プロピルセルロース ２５．００１１！９実施
例 ５
インドメタシン ５０ｆ１低置換度ヒドロキシプロピル
セルロース ７５？及び乳糖９０７から成る均質な粉末
混合物を調製し、常法により顆粒化した。別にメタケイ
酸アルミン酸マグネシウム１Ｑ Ｏｆ、軽質無水ケイ酸
１０？を均質化した。Indomethacin 25.0OWl Aluminum metasilicate/magnesium acid 25.00■ Milk
Sugar 875.00■
Light anhydrous silicic acid 5000■Hydroxypropyl cellulose 25.0011!9 Example 5 Indomethacin 50f1 Low substituted hydroxypropyl cellulose 75? A homogeneous powder mixture consisting of lactose and lactose 907 was prepared and granulated using conventional methods. Separately, magnesium metasilicate aluminate 1Q Of, light silicic anhydride 10? was homogenized.
２つの粉末混合物を合わせ、さらに、メルク１５２を加
えて混合均質化した後、常法により、直径８瓢２重量１
７０１９（Ｑ以下の処方に示す錠剤２０００錠を打錠し
た。The two powder mixtures were combined, and Merck 152 was added thereto for mixing and homogenization.
7019 (2000 tablets shown in the following formulation were compressed.
インドメタシン ２５．００キメタケ
イ酸アルミン酸マグネシウム ５０． ＯＯ■低
ｉ換度ヒドロキシプロピルセルロース ３７．５０■
乳 糖 ４５
．００■軽質無水ケイ酸 ５、ｏｏ
■タルク ７．５ｏ■１７
０、００■
試験例
（試験薬剤）
対照薬剤：実施例１の記載の方法に従って、製造した下
記の組成のカプセル製剤。Indomethacin 25.00 Magnesium aluminate kimetasilicate 50. OO ■ Low i conversion hydroxypropyl cellulose 37.50 ■
Lactose 45
．． 00 ■ Light silicic anhydride 5, oo
■Talc 7.5o■17
0,00■ Test Example (Test drug) Control drug: Capsule preparation with the following composition manufactured according to the method described in Example 1.
インドメタシン ２５．００■低ｉ換
ｉヒドロキシプロピルセルロース ３５．００１ｎｇ乳
ｍ ７６．
ｙ ｓ■軽質無水ケイ酸 ２．２５
■タルク ６．００■１４
５．００７’９
試験製剤Ａ：実施例１の記載の方法に従って、製造した
下記組成のカプセル製剤。Indomethacin 25.00 ■ Low i-hydroxypropyl cellulose 35.001 ng milk m 76.
y s ■ Light silicic anhydride 2.25
■Talc 6.00■14
5.007'9 Test formulation A: A capsule formulation having the following composition, manufactured according to the method described in Example 1.
インドメタシン２５．００ｍ９
メタケイ酸アルミン酸マグネ７ウム ２．５０
■低ｒｔ換度ヒドロキシグロピルセルロース ３５０
０■乳 糖 ７
６７５巧軽質無水ケイ酸 ２２５η
１４７、５０■
試験製剤Ｂ：実施例１のカプセル製剤。Indomethacin 25.00m9 Magnesium aluminate metasilicate 2.50
■Low rt conversion hydroxyglopy cellulose 350
0 ■ Lactose 7
675 Light silicic anhydride 225η
147,50■ Test formulation B: Capsule formulation of Example 1.
試験製剤Ｃ：実施例２のカプセル製剤。Test formulation C: Capsule formulation of Example 2.
これら４つの製剤について雌性ピーグル大会４頭を用い
て、バイオアベイラビリティ−評価を実施した。A bioavailability evaluation of these four formulations was conducted using four female female peagles.
（方 法）
体重約１０Ｋｇの雌性ピーグル犬を投与前日よシ、１８
時間絶食させ、その後、試験製剤を水約１００−ととも
に経口投与した。投与後の犬の状態は良好で吐くことは
なかった。(Method) A female peagle dog weighing approximately 10 kg was administered on the day before administration.
After fasting for an hour, the test formulation was orally administered with approximately 100 mL of water. The dog was in good condition after administration and did not vomit.
採血は投与前、及び投与後、０．５，１，２，３゜４．
６．８時間毎に前肢静脈より、ヘパリン処理注射筒にて
行なった。採血した血液は、３０００ｒｐｍで１０分間
遠心分離し、その血漿中のインドメタシン量を高速液体
クロマトグラフィー法により定量した。その結果を表１
および図１に示しだ。Blood was collected at 0.5, 1, 2, 3 degrees before and after administration.4.
Testing was performed every 6.8 hours via a forelimb vein using a heparinized syringe. The collected blood was centrifuged at 3000 rpm for 10 minutes, and the amount of indomethacin in the plasma was determined by high performance liquid chromatography. Table 1 shows the results.
and shown in Figure 1.
図１は、実施例で調製した裂創および対照剤についての
バイオアベイラビリティ−試験結果を示す血中濃度−時
間特性図である。
特許出願人 大正裂薬株式会社
代理人 弁理士 北 川 富 遣口 １FIG. 1 is a blood concentration-time characteristic diagram showing the bioavailability test results for the laceration wounds prepared in Examples and the control agent. Patent applicant Taisho Rakuyaku Co., Ltd. Agent Patent attorney Tomi Kitagawa Yariguchi 1
Claims (1)
ケイ酸アルミン酸マグネシウムを配合することを特徴と
する経口製剤。1) An oral preparation characterized in that 20 to 300% by weight of magnesium aluminate metasilicate is blended with indomethacin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61202143A JPS6357521A (en) | 1986-08-28 | 1986-08-28 | Oral preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61202143A JPS6357521A (en) | 1986-08-28 | 1986-08-28 | Oral preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS6357521A true JPS6357521A (en) | 1988-03-12 |
Family
ID=16452670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61202143A Pending JPS6357521A (en) | 1986-08-28 | 1986-08-28 | Oral preparation |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6357521A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005105102A1 (en) * | 2004-05-04 | 2005-11-10 | Equitech Corporation | Improved nsaid composition |
| WO2006056042A1 (en) * | 2004-11-03 | 2006-06-01 | Equitech Corporation | Nsaid compositions exhibiting clinical superiority |
| WO2006100875A1 (en) * | 2005-03-24 | 2006-09-28 | Daiichi Sankyo Company, Limited | Pharmaceutical composition |
| WO2009055925A1 (en) * | 2007-10-31 | 2009-05-07 | Equitech Corporation | Enhanced nsaid formulations |
-
1986
- 1986-08-28 JP JP61202143A patent/JPS6357521A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005105102A1 (en) * | 2004-05-04 | 2005-11-10 | Equitech Corporation | Improved nsaid composition |
| WO2006056042A1 (en) * | 2004-11-03 | 2006-06-01 | Equitech Corporation | Nsaid compositions exhibiting clinical superiority |
| WO2006100875A1 (en) * | 2005-03-24 | 2006-09-28 | Daiichi Sankyo Company, Limited | Pharmaceutical composition |
| WO2009055925A1 (en) * | 2007-10-31 | 2009-05-07 | Equitech Corporation | Enhanced nsaid formulations |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1306686C (en) | Pharmaceutical composition containing ibuprofen | |
| JP4209467B2 (en) | Formulation composition for oral administration | |
| JPS59101423A (en) | Novel solid pharmaceutical preparation of nifedipine | |
| KR100465895B1 (en) | Swallow tablet comprising paracetamol | |
| IE48879B1 (en) | An analgesic effervescent powder and process for its preparation | |
| WO2006133954A2 (en) | Diclofenac formulations and methods of use | |
| IE63799B1 (en) | Use of thromboxane a2 receptor antagonists for the preparation of a pharmaceutical composition for treating skin injuries | |
| KR100347631B1 (en) | Combined antipyretic analgesic drug | |
| JPS62298530A (en) | Pharmaceutical composition for suppository | |
| JPS6357521A (en) | Oral preparation | |
| JPH0678233B2 (en) | Pharmaceutical preparation having antihypertensive and cardioprotective effects | |
| CZ270999A3 (en) | Pharmaceutical preparations containing ibuprofen and domperidone for treating migraine | |
| JPH0256328B2 (en) | ||
| JPH0560810B2 (en) | ||
| JPS618A (en) | Nifedipin-containing drug preparation | |
| JPH11158066A (en) | Pharmaceutical product containing ibuprofen | |
| JPS59210022A (en) | Sustained release theophylline pharmaceutical | |
| EP0319074A1 (en) | Pharmaceutical composition and process for its preparation | |
| JPH07126159A (en) | Emulsion ointment | |
| JP3947244B2 (en) | Preparation for peptic ulcer treatment | |
| JPS6165819A (en) | Drug composition containing organic germanium compound | |
| JP2750130B2 (en) | Composition for oral administration | |
| JPS6026770B2 (en) | Gastrointestinal ulcer treatment | |
| JPH1059862A (en) | Cyclosporin preparation | |
| JPH1045580A (en) | Production of carnitine chloride-containing pharmaceutical preparation |